Drug intelligence / Profile preview

hydroxyurea + infliximab

Development stage: Preclinical
Lead developer: Janssen Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy using hydroxyurea and infliximab. Hydroxyurea is an antimetabolite that interferes with cell growth and is used to treat sickle cell anemia, chronic myeloid leukemia, and certain cancers. Infliximab is a TNF-alpha inhibitor used to treat various inflammatory conditions. When combined, they may provide enhanced therapeutic effects for conditions like recalcitrant psoriasis, though with increased risk of immunosuppression.

Targets

RNR (Ribonucleotide reductase)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on hydroxyurea + infliximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydroxyurea + infliximab.

Explore the full profile